Optimal follow-up time to determine the sustained virological response in patients with chronic hepatitis C receiving pegylated-interferon and ribavirin

Journal of Gastroenterology and Hepatology (Australia)

Volumn 27, Issue 1, 2012, Pages 69-75

  Namikawa, Masashi ^a,b   Kakizaki, Satoru ^a   Yata, Yutaka ^b   Yamazaki, Yuichi ^a   Horiguchi, Norio ^a   Sato, Ken ^a   Takagi, Hitoshi ^a   Mori, Masatomo ^a  

^a GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b SAISEIKAI MAEBASHI HOSPITAL   (Japan)

Author keywords

Chronic hepatitis C; Peg interferon; Real time polymerase chain reaction; Ribavirin; Sustained virological response

Indexed keywords

ALANINE AMINOTRANSFERASE; INTERLEUKIN 28; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; DRUG EFFICACY; FEMALE; FOLLOW UP; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PATIENT COMPLIANCE; PREDICTIVE VALUE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS LOAD;

EID: 84155178374     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2011.06802.x     Document Type: Article

References (24)

1. Marcellin P. Hepatitis C: the clinical spectrum of the disease. J. Hepatol. 1999; 31: 9-16.
2. Marcellin P, Boyer N, Gervais A etal. Long-term histological improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann. Intern. Med. 1997; 127: 875-81.
3. Maylin S, Martinot-Peignoux M, Moucari M etal. Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C. Gastroenterology 2008; 135: 821-9.
4. Suzuki H, Kakizaki S, Horiguchi N etal. Clinical characteristics of null responders to Peg-IFNα2b/ribavirin therapy for chronic hepatitis C. World J. Hepatol. 2010; 2: 401-5.
5. Ghany MG, Strader DB, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases. Diagnosis, management and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-74.
6. Reichard O, Glaumann H, Fryden A, Norkrans G, Wejstal R, Weiland O. Long-term follow-up of chronic hepatitis C patients with sustained virological response to alpha-interferon. J. Hepatol. 1999; 30: 783-7.
7. McHutchison JG, Poynard T, Esteban-Mur R etal. International Hepatitis Interventional Therapy Group. Hepatic HCV RNA before and after treatment with interferon alone or combined with ribavirin. Hepatology 2002; 35: 688-93.
8. Martinot-Peignoux M, Stern C, Maylin S etal. Twelve weeks posttreatment follow-up is as relevant as 24weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin. Hepatology 2010; 51: 1122-6.
9. Bortoletto G, Campagnolo D, Mirandola S etal. Comparable performance of TMA and Real-Time PCR in detecting minimal residual hepatitis C viraemia at the end of antiviral therapy. J. Clin. Virol. 2011; 50: 217-20.
10. Sandres-Sauné K, Abravanel F, Nicot F etal. Detection and quantitation of HCV RNA using real-time PCR after automated sample processing. J. Med. Virol. 2007; 79: 1821-6.
11. Sizmann D, Boeck C, Boelter J etal. Fully automated quantification of hepatitis C virus (HCV) RNA in human plasma and human serum by the COBAS AmpliPrep/COBAS TaqMan system. J. Clin. Virol. 2007; 38: 326-33.
12. Ogawa E, Furusyo N, Toyoda K etal. Excellent superiority and specificity of COBAS TaqMan HCV assay in an early viral kinetic change during pegylated interferon alpha-2b plus ribavirin treatment. BMC Gastroenterol. 2010; 10: 38.
13. Kumada H, Okanoue T, Onji M etal. The Study Group for the Standardization of Treatment of Viral Hepatitis Including Cirrhosis, Ministry of Health, Labour and Welfare of Japan. Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis C virus infection for the fiscal year 2008 in Japan. Hepatol. Res. 2010; 40: 8-13.
14. Wai CT, Greenson JK, Fontana RJ etal. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518-26.
15. Ohnishi Y, Tanaka T, Ozaki K, Yamada R, Suzuki H, Nakamura Y. A high-throughput SNP typing system for genome-wide association studies. J. Hum. Genet. 2001; 46: 471-7.
16. Suzuki A, Yamada R, Chang X etal. Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis. Nat. Genet. 2003; 34: 395-402.
17. Sabato MF, Shiffman ML, Langley MR, Wilkinson DS, Ferreira-Gonzalez A. Comparison of performance characteristics of three Real-Time reverse transcription-PCR test systems for detection and quantification of hepatitis C virus. J. Clin. Virol. 2007; 45: 2529-36.
18. Chevaliez S, Bouvier-Alias M, Pawlotsky JM. Performance of the Abbott Real-Time PCR assay using m2000sp and m2000rt for hepatitis C virus RNA quantification. J. Clin. Microbiol. 2009; 47: 1726-32.
19. Zeuzem S, Heathcote EJ, Shiffman ML etal. Twelve weeks follow-up is sufficient for the determination of sustained virologic response in patients treated with interferon alpha for chronic hepatitis C. J. Hepatol. 2003; 39: 106-11.
20. Sezaki H, Suzuki F, Kawamura Y etal. Poor response to pegylated interferon and ribavirin in older women infected with hepatitis C virus of genotype 1b in high viral loads. Dig. Dis. Sci. 2009; 54: 1317-24.
21. Yamada G, Iino S, Okuno T etal. Virological response in patients with hepatitis C virus genotype 1b and a high viral load: impact of peginterferon-alpha-2a plus ribavirin dose reductions and host-related factors. Clin. Drug. Investig. 2008; 28: 9-16.
22. Oze T, Hiramatsu N, Yakushijin T etal. Indications and limitations for aged patients with chronic hepatitis C in pegylated interferon alfa-2b plus ribavirin combination therapy. J. Hepatol. 2011; 54: 604-11.
23. Ge D, Fellay J, Thompson AJ etal. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
24. Tanaka Y, Nishida N, Sugiyama M etal. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat. Genet. 2009; 41: 1105-9.